<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04821960</url>
  </required_header>
  <id_info>
    <org_study_id>STU00214078</org_study_id>
    <nct_id>NCT04821960</nct_id>
  </id_info>
  <brief_title>Memory and Fear Study (Fear of Memory Loss Study)</brief_title>
  <official_title>Improving Emotional Well-being and Quality of Life in Older Adults Experiencing Dementia-related Fear.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized control study to determine the impact of a tailored, web-based&#xD;
      mindfulness program to reduce anxiety and increase the quality of life in older adults&#xD;
      experiencing dementia-related fears, relative to a conventional meditation program.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will test two different types of online mindfulness programs to see if an online&#xD;
      self-paced mindfulness program can help reduce anxiety related to memory loss. Participants&#xD;
      will be involved in the study for a total of 10 weeks. Participants will log on to an online&#xD;
      mindfulness program 4 days per week for about 10-20 minutes each. The total program will last&#xD;
      3 weeks. Participants will also be asked to complete questionnaires before starting the&#xD;
      program, during the program, and after they complete the program.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 17, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Fear and Avoidance of Memory Loss (FAM) Scale score at follow-up</measure>
    <time_frame>10 Weeks Post-Baseline</time_frame>
    <description>A 24-item scale to assess fear of memory loss. Scores range from 24-120 points with a higher score indicating a higher fear of memory loss.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of Fear of Alzheimer's Disease Scale (FADS) score at follow-up</measure>
    <time_frame>10 Weeks Post-Baseline</time_frame>
    <description>A 30-item scale to assess fear of Alzheimer's disease. Minimum score = 0; maximum score = 120. A higher score indicates a greater fear of developing Alzheimer's Disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Memory Failure Scale (MFS)</measure>
    <time_frame>10 Week Post-Baseline</time_frame>
    <description>A 12-item scale that measures memory failure that people tend to experience in everyday life. Minimum score=12; maximum score= 60. A higher score indicates a greater likelihood of memory failures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcome Measures Information System-29 (PROMIS-29)</measure>
    <time_frame>10 Weeks Post-Baseline</time_frame>
    <description>A 29-item scale to assess quality of life, social functioning, fatigue, anxiety, and depression. Each item has 5 answer options (from 1 to 5). From the sum of the answers to each question in the domain, the total raw score for each domain is calculated, resulting in each domain score between 4 and 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>World Health Organization Well-Being Index (WHO-5)</measure>
    <time_frame>10 Weeks Post-Baseline</time_frame>
    <description>A 5-item scale to assess overall well-being. Minimum raw score = 0; maximum raw score = 25. Raw scores are multiplied by 4 to give a final score from 0 (representing the worst well-being) to 100 (representing the best well-being).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGIC)</measure>
    <time_frame>Follow-up (4 weeks)</time_frame>
    <description>To assess participant's impression of change in their fear and anxiety since the start of the intervention. This scale is 1-item. Minimum score = 1; maximum score = 5. A higher score indicates the best change since starting the intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronavirus Anxiety Scale (CAS)</measure>
    <time_frame>10 Weeks Post-Baseline</time_frame>
    <description>A 5-item self-report mental health screener of dysfunctional anxiety associated with the coronavirus crisis. This scale is 5-items. Minimum score = 0; maximum score = 20. A higher score indicates higher dysfunctional coronavirus-related anxiety.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Anxiety and Fear</condition>
  <arm_group>
    <arm_group_label>Conventional Mindfulness Program</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Routine mindfulness lessons and activities.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tailored Mindfulness Program for Fear of Memory Loss</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tailored mindfulness lessons and activities for fear of memory loss.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Tailored Mindfulness Program for Fear of Memory Loss</intervention_name>
    <description>The tailored mindfulness program has been specifically created to focus on fear of memory loss compared to general mindfulness lessons and activities.</description>
    <arm_group_label>Tailored Mindfulness Program for Fear of Memory Loss</arm_group_label>
    <other_name>Conventional Mindfulness Program</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Conventional Mindfulness Program</intervention_name>
    <description>Routine non-tailored mindfulness lessons and activities.</description>
    <arm_group_label>Conventional Mindfulness Program</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  55 years of age or older&#xD;
&#xD;
          -  Elevated dementia-related fear&#xD;
&#xD;
          -  Able to read/write in English&#xD;
&#xD;
          -  Willingness to be randomized to intervention group&#xD;
&#xD;
          -  Willingness to complete three weeks of self-guided intervention, questionnaires, and&#xD;
             cognitive tests.&#xD;
&#xD;
          -  Access to a reliable internet connection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of mild cognitive impairment, Alzheimer's Disease, or dementia by a&#xD;
             healthcare provider.&#xD;
&#xD;
          -  Impaired cognitive or neurologic function&#xD;
&#xD;
          -  Unstable medical condition&#xD;
&#xD;
          -  Severe depression&#xD;
&#xD;
          -  Current treatment for anxiety or depression&#xD;
&#xD;
          -  Current participation in another psychotherapy&#xD;
&#xD;
          -  Current use of psychiatric medication&#xD;
&#xD;
          -  Current substance use disorder&#xD;
&#xD;
          -  Inadequate vision or hearing to interact with study materials&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michelle Taddeo, MPH</last_name>
    <phone>312-503-1469</phone>
    <email>michelle.taddeo@northwestern.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Melissa Marquez, MBA</last_name>
    <phone>312-503-7678</phone>
    <email>melissa.marquez@northwestern.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Taddeo, MPH</last_name>
      <phone>312-503-1469</phone>
      <email>michelle.taddeo@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>James W Griffith, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2021</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>James W Griffith</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Mindfulness</keyword>
  <keyword>Fear of memory loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memory Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>De-identified data may be shared with other researchers.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 1, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT04821960/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 1, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT04821960/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

